-
HETEROGENEOUS RESPONSES TO BRAZIL’S PHARMACEUTICAL PRICE CAP REGULATION: EVIDENCE FROM PRIVATE INSURANCES AND THE UNIFIED HEALTH SYSTEM
Mar 18, 2026, 21:38 PM -
COST-EFFECTIVENESS OF INAVOLISIB IN THE TREATMENT OF PIK3A-MUTATED, HR+/HER2-ABC LOCALLY ADVANCED OR METASTATIC BREAST CANCER IN THE US
Mar 18, 2026, 21:38 PM -
QUANTIFYING CDA-INESSS DIFFERENCES IN ONCOLOGY HTA: RECOMMENDATIONS, RE-ANALYSIS, AND PRICE REDUCTIONS (2024-2025)
Mar 18, 2026, 21:38 PM -
ACCESS TO GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST ANTIOBESITY MEDICATIONS: FORMULARY COVERAGE AND PRIOR AUTHORIZATION RESTRICTIONS ACROSS U.S. PAYERS
Mar 18, 2026, 21:38 PM -
A LANDSCAPE ASSESSMENT OF THE STATISTICAL AND ECONOMIC MODELING OF CURE IN ONCOLOGY
Mar 18, 2026, 21:38 PM -
REAL-WORLD CONCORDANCE WITH THE FRAMINGHAM STROKE RISK MODEL IN ATRIAL FIBRILLATION AND IDENTIFICATION OF ADDITIONAL SIGNIFICANT FEATURES
Mar 18, 2026, 21:38 PM -
DEVELOPMENT OF A MULTI-AGENT "DEEP" AI SYSTEM FOR HEOR EVIDENCE AND INTELLIGENCE GENERATION
Mar 18, 2026, 21:38 PM -
UNDERSTANDING THE GLOBAL ECONOMIC BURDEN OF HEPATITIS DELTA VIRUS: A SYSTEMATIC LITERATURE REVIEW
Mar 18, 2026, 21:38 PM -
COST-EFFECTIVENESS ANALYSIS OF DPYD-GUIDED FOLFOX IN UNRESECTABLE METASTATIC COLORECTAL CANCER IN THE US: A PATIENT-LEVEL MICROSIMULATION MODEL
Mar 18, 2026, 21:38 PM -
COST-EFFECTIVENESS OF PROCALCITONIN-GUIDED ANTIBIOTIC THERAPY IN ADULT PATIENTS WITH ACUTE RESPIRATORY INFECTION IN A COLOMBIAN REFERRAL HOSPITAL
Mar 18, 2026, 21:38 PM -
A SYSTEMATIC REVIEW OF FINDINGS AND METHODS IN ECONOMIC EVALUATIONS OF DYADIC HEALTHCARE INTERVENTIONS
Mar 18, 2026, 21:38 PM -
HUMANISTIC BURDEN IN PATIENTS WITH PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE (PH-ILD) USING PATIENT-REPORTED OUTCOME MEASURES (PROMS)
Mar 18, 2026, 21:38 PM -
THE COST-EFFECTIVENESS OF CONTINUOUS GLUCOSE MONITORING (CGM) FOR ADULTS WITH TYPE 1 DIABETES IN IRELAND
Mar 18, 2026, 21:38 PM -
MODELLING HEALTH SYSTEM CAPACITY AND MEASUREMENT DISPERSION TO EXPLAIN CROSS-NATIONAL VARIATION IN EQVT UTILITY VALUES
Mar 18, 2026, 21:38 PM -
COST-EFFECTIVENESS OF SEMAGLUTIDE 2.4 MG COMPARED WITH RESMETIROM AND STANDARD OF CARE FOR METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) IN THE U.S. USING MOST FAVORED NATION (MFN) PRICING
Mar 18, 2026, 21:38 PM -
REAL-WORLD DIAGNOSTIC DELAY, TREATMENT ACCESS, AND HEALTH SYSTEM BURDEN IN PRIMARY IMMUNODEFICIENCY/INBORN ERRORS OF IMMUNITY: EVIDENCE FROM THE UNITED STATES AND EX-US SETTINGS
Mar 18, 2026, 21:38 PM -
WHEN IS REAL-WORLD EVIDENCE SCIENTIFICALLY SOUND? EXPERT CONSENSUS ON SASS FOR CFL COMMUNICATION
Mar 18, 2026, 21:38 PM -
AN INDIRECT TREATMENT COMPARISON (ITC) OF IFINATAMAB DERUXTECAN (I-DXD) VERSUS REAL-WORLD PHYSICIAN’S CHOICE OF THERAPY (RWPCT) IN PATIENTS PREVIOUSLY TREATED WITH AT LEAST 2 LINES OF THERAPY (LOTS) FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER...
Mar 18, 2026, 21:38 PM -
THE EXTENT OF TREATMENT RESPONSE AND PREFERENCE HETEROGENEITY IN MAJOR DEPRESSIVE DISORDER: IMPLICATIONS FOR POPULATION-LEVEL RESOURCE ALLOCATION
Mar 18, 2026, 21:38 PM -
REAL-WORLD OUTCOMES OF SECOND-LINE THERAPIES IN RELAPSED/REFRACTORY DLBCL PATIENTS IN GERMANY: IMPACT OF FRONT-LINE TREATMENT-FREE PERIOD (2020-2022)
Mar 18, 2026, 21:38 PM
